Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Patel, T. Hensing, F. Rademaker, E. Hart, C. Obasaju, J. Treat, D. Milton, P. Bonomi (2008)
Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
M. Fidler, S. Basu, L. Buckingham, K. Kaiser, S. McCormack, J. Coon, P. Bonomi (2008)
Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinibJournal of Clinical Oncology, 26
N. Ferrer, A. Paredes, J. Muñoz-Langa, M. Méndez, M. Cobo, T. de-Portugal, V. Giner, S. García, R. Gallego, J. Torrego (2008)
Bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (pts) with advanced or metastatic, non squamous, non-small-cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
T. Hida, I. Okamoto, T. Kashii, M. Satouchi, Y. Ichinose, N. Katakami, M. Ando, T. Kurata, K. Nakagawa, M. Fukuoka (2008)
Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOGJournal of Clinical Oncology, 26
W. Akerley, C. Langer, Y. Oh, D. Strickland, S. Royer, Q. Xia, Y. Mu, Jane Huang, M. Socinski (2008)
Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancerJournal of Clinical Oncology, 26
P. Jänne, G. Simon, C. Langer, R. Taub, A. Dowlati, P. Fidias, M. Monberg, C. Obasaju, H. Kindler (2008)
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 9
J. Polikoff, J. Hainsworth, L. Fehrenbacher, S. Royer-Joo, Y. Mu, D. Strickland, V. Miller (2008)
Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLASJournal of Clinical Oncology, 26
J. Waples, M. Auerbach, R. Steis, R. Boccia, R. Wiggans (2008)
A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04–015)Journal of Clinical Oncology, 26
D. Karp, L. Paz-Ares, S. Novello, P. Haluska, L. Garland, F. Cardenal, L. Blakely, P. Eisenberg, A. Gualberto, C. Langer (2008)
High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLCJournal of Clinical Oncology, 26
É. Dansin, J. Mezger, D. Isla, F. Barlesi, A. Bearz, P. López, J. Laskin, N. Pavlakis, N. Thatcher, L. Crinò (2008)
Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)Journal of Clinical Oncology, 26
M. Maio, P. Chiodini, V. Georgoulias, D. Hatzidaki, K. Takeda, F. Wachters, V. Gebbia, A. Morabito, F. Perrone, C. Gridelli (2008)
Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data of five randomized trialsJournal of Clinical Oncology, 26
J. Douillard, V. Hirsh, T. Mok, M. Socinski, C. Watkins, E. Lowe, A. Armour, Edward Kim (2008)
Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST)Journal of Clinical Oncology, 26
V. Miller, H. Wakelee, P. Lara, John Cho, N. Chowhan, D. Costa, N. Vrindavanam, R. Yanagihara, N. Pennell, T. Lynch (2008)
Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trialJournal of Clinical Oncology, 26
M. Barve, J. Bender, B. Pappen, G. Ishioka, M. Morse, F. Greco, D. McCune, R. Steis, H. Khong, J. Nemunaitis (2008)
Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patientsJournal of Clinical Oncology, 26
Y. Soon, M. Stockler, M. Boyer, L. Askie (2008)
Duration of chemotherapy for advanced non-small cell lung cancer: An updated systematic review and meta-analysisJournal of Clinical Oncology, 26
P. Jänne, J. Schellens, J. Engelman, S. Eckhardt, R. Millham, L. Denis, C. Britten, Steven Wong, D. Boss, D. Camidge (2008)
Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLCJournal of Clinical Oncology, 26
T. Kimura, C. Mahaffey, B. Pryde, P. Mack, A. Davies, D. Gandara, P. Gumerlock (2004)
Apoptotic effects of the docetaxel->OSI-774 combination in non-small cell lung carcinoma (NSCLC) cellsJournal of Clinical Oncology, 22
T. Ciuleanu, T. Brodowicz, C. Belani, J. Kim, M. Krzakowski, E. Laack, Yi-long Wu, P. Peterson, S. Adachi, C. Zielinski (2008)
Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III studyJournal of Clinical Oncology, 26
V. Tzekova, C. Cebotaru, T. Ciuleanu, D. Damjanov, H. Ganchev, Vladimir Kanarev, P. Stella, N. Sanders, G. Pover, J. Hainsworth (2008)
Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
PH Gumerlock, BJ Pryde, T Kimura (2003)
Enhanced cytotoxicity of Docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC)Proc Am Soc Clin Oncol, 22
O. Merimsky, C. Cheng, M. Reck, S. Au, J. Pawel (2008)
Erlotinib as 1st-line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
J Heymach, E Narran, H Mann (2008)
Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patinets with advanced NSCLCJ Clin Oncol, 26
F. Marinis, H. Raftopoulos, E. Bria, C. Gridelli, A. Rossi, F. Grossi, R. Gralla (2008)
Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator armsJournal of Clinical Oncology, 26
J. Heymach, L. Paz-Ares, F. Braud, M. Sebastian, D. Stewart, W. Eberhardt, A. Ranade, G. Cohen, J. Trigo, A. Sandler, P. Bonomi, R. Herbst, A. Krebs, J. Vasselli, B. Johnson (2008)
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 33
A. Adjei, S. Mandrekar, G. Dy, J. Molina, D. Gandara, K. Ziegler, P. Stella, K. Rowland, S. Schild, R. Zinner (2008)
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG studyJournal of Clinical Oncology, 26
M. Barve, J. Bender, N. Senzer, C. Cunningham, F. Greco, D. McCune, R. Steis, H. Khong, D. Richards, J. Stephenson, P. Ganesa, Jackie Nemunaitis, G. Ishioka, B. Pappen, M. Nemunaitis, M. Morse, B. Mills, P. Maples, J. Sherman, J. Nemunaitis (2008)
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 27
D. Pfister, David Johnson, C. Azzoli, W. Sause, Thomas Smith, Sherman Baker, J. Olak, D. Stover, John Strawn, A. Turrisi, M. Somerfield (2004)
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 2
E. Smit, H. Groen, H. Smit, B. Biesma, P. Eppinga, A. Dingemans, N. Walree, A. Vincent, N. Zandwijk (2008)
A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung cancer (NSCLC)- NVALT 7Journal of Clinical Oncology, 26
R. Rosell, C. Daniel, R. Ramlau, A. Szczesna, M. Constenla, Bertrand Mennecier, W. Pfeifer, M. Mueser, I. Montaner, U. Gatzemeier (2004)
Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
A. Sandler, D. Johnson, J. Brahmer, J. Schiller, M. Ostland, R. Gray, S. Tran, I. Dimery (2006)
Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
V. Hirsh, M. Boyer, R. Rosell, R. Benner, D. Readett, J. Schiller (2008)
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
D. Lee, S. Kim, K. Park, J. Kim, J. Lee, S. Shin, J. Kang, C. Suh, M. Ahn, J. Ahn (2008)
A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapyJournal of Clinical Oncology, 26
J. Lee, J. Ignacio, Chong-Jen Yu, Caicun Zhou, Yi-long Wu, Yuh-Min Chen, Li Zhang, K. Jin, M. Johnston, T. Mok (2008)
FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
D. Tassinari, C. Santelmo, E. Tamburini, C. Possenti, L. Agli (2008)
Outcomes of second line chemotherapy (II-LC) in platinum resistant non small cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
GJ Riely, MG Kris, JL Marks (2008)
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinomaJ Clin Oncol, 26
Gregory Riely, M. Kris, D. Rosenbaum, J. Marks, Allan Li, D. Chitale, K. Nafa, E. Riedel, M. Hsu, W. Pao, V. Miller, M. Ladanyi (2008)
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung AdenocarcinomaClinical Cancer Research, 14
D. Solit, Y. She, Jose Lobo, M. Kris, H. Scher, N. Rosen, F. Sirotnak (2005)
Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to PaclitaxelClinical Cancer Research, 11
V. Archer, M. Reck, A. Sandler, David Johnson, G. Kong, D. Strickland, J. Bennouna (2008)
Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapyJournal of Clinical Oncology, 26
P. Delmar, E. Tan, A. Płużańska, R. Ramlau, M. Reck, P. Mcloughlin, J. Baselga (2008)
MERIT: Analysis of differential gene expression in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with erlotinibJournal of Clinical Oncology, 26
A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, S. Sadetzki (2008)
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 1
R. Pirker, A. Szczesna, J. Pawel, M. Krzakowski, R. Ramlau, Kyung-Ah Park, U. Gatzemeier, E. Bajeta, M. Emig, J. Pereira (2008)
FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 26
This congress report gives an overview of the most important news concerning lung cancer presented at ASCO 2008 meeting. The most interesting highlights were: (1) For the 1st-line treatment of patients with advanced NSCLC, Cetuximab, added to a platinum-based chemotherapy, sets a new standard and side effects (like acne-like rash) were as expected and manageable. (2) Insulin-like growth factor type I receptor (IGF-IR) in combination with chemotherapy could be an optimistic therapeutic option for NSCLC with squamous cell histology since first results proved a response rate of 72% in this histological subtype. (3) Erlotinib as 1st-line treatment for elderly patients showed encouraging efficacy. (4) For patients without progression after the first line regimen, early introduction of a second line agent is an efficient novel therapeutic option. Further validating studies are warranted.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jan 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.